Detail akcie Northwest Biotherapeutics Inc, Ordinary, OTC Markets Group Inc - OTCQB online

Business Summary: Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and includes treatment of a diverse range of more than a dozen types of cancers. Its platform technology, DCVax, is a personalized immune therapy that uses a patient’s own dendritic cells, or DCs, the master cells of the immune system, as the therapeutic agent. Its subsidiaries include Flaskworks LLC, NW Bio GmbH, and others.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Northwest Biotherapeutics Inc revenues decreased 39% to $706K. Net loss applicable to common stockholders increased 11% to $62.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Loss from extinguishment of debt increase of 60% to $15.8M (expense).